利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.024 秒)

    Secretion of hirudin derivatives
    11.
    发明授权
    Secretion of hirudin derivatives 失效
    水蛭素衍生物的分泌

    公开(公告)号：US5919895A

    公开(公告)日：1999-07-06

    申请号：US982064

    申请日：1992-11-25

    申请人： Gerhard Schmid ,  Paul Habermann

    发明人： Gerhard Schmid ,  Paul Habermann

    IPC分类号： C07K14/195 ,  A61P7/02 ,  C07K14/005 ,  C07K14/815 ,  C12N1/21 ,  C12N9/10 ,  C12N15/00 ,  C12N15/09 ,  C12N15/15 ,  C12N15/71 ,  C12N15/72 ,  C12P21/02 ,  C12R1/19 ,  A61K38/58

    CPC分类号： C12N9/1074 ,  C07K14/815 ,  C07K2319/02

    摘要： A process for obtaining hirudin derivatives from E. coli secretor mutants which entails:(1) construction of a recombinant vector on which there is located the gene coding for a hirudin derivative directly downstream of a DNA section which codes for a bacterial signal peptide;(2) transformation of an E. coli secretor mutant with the recombinant vector constructed in step (1);(3) cultivation of the transformed cells in a medium; and(4) obtaining the hirudin derivative from the medium; anda recombinant vector which contains one or more copies of a gene construct which codes for a protein consisting of a bacterial signal peptide and of a hirudin derivative, and a hirudin derivative with the N-terminal amino-acid sequence A-(SEQ ID NO: 5) in which A represents Ala, Gln, His, Phe, Tyr, Glu, Ser, Asp or Asn.

    摘要翻译： 从大肠杆菌分泌突变体获得水蛭素衍生物的方法，其需要：（1）构建重组载体，其上定位编码细菌信号肽的DNA区段下游的水蛭素衍生基因; （2）用步骤（1）中构建的重组载体转化大肠杆菌分泌突变体; （3）培养基中的转化细胞; 和（4）从培养基中获得水蛭素衍生物; 和含有编码由细菌信号肽和水蛭素衍生物组成的蛋白质的基因构建体的一个或多个拷贝的重组载体，以及具有N-末端氨基酸序列A-（SEQ ID NO）的水蛭素衍生物 ：5）其中A代表Ala，Gln，His，Phe，Tyr，Glu，Ser，Asp或Asn。

    Secretion of hirudin derivatives
    12.
    发明授权
    Secretion of hirudin derivatives 失效
    水蛭素衍生物的分泌

    公开(公告)号：US06514730B1

    公开(公告)日：2003-02-04

    申请号：US09286097

    申请日：1999-04-02

    申请人： Gerhard Schmid ,  Paul Habermann

    发明人： Gerhard Schmid ,  Paul Habermann

    IPC分类号： C12P2102

    CPC分类号： C07K14/815

    摘要： A process for obtaining hirudin derivatives from E. coli secretor mutants which entails: (1) construction of a recombinant vector on which there is located the gene coding for a hirudin derivative directly downstream of a DNA section which codes for a bacterial signal peptide; (2) of an E. coli secretor mutant with the recombinant vector constructed in step (1); (3) cultivation of the transformed cells in a medium; and (4) obtaining the hirudin derivative from the medium; and a recombinant vector which contains one or more copies of a gene construct which codes for a protein consisting of a bacterial signal peptide and of a hirudin derivative, and a hirudin derivative with the N-terminal amino-acid sequence A—(SEQ ID NO: 5) in which A represents Ala, Gln, His, Phe, Tyr, Glu, Ser, Asp or Asn.

    摘要翻译： 从大肠杆菌分泌突变体获得水蛭素衍生物的方法，其需要：（1）构建重组载体，其上定位有编码细菌信号肽的DNA区直接下游的水蛭素衍生基因的基因;（ 2）具有在步骤（1）中构建的重组载体的大肠杆菌分泌突变体;（3）在培养基中培养转化的细胞; 和（4）从培养基中获得水蛭素衍生物; 和含有编码由细菌信号肽和水蛭素衍生物组成的蛋白质的基因构建体的一个或多个拷贝的重组载体和具有N-末端氨基酸序列A-（SEQ ID NO：1）的水蛭素衍生物， 5）其中A代表Ala，Gln，His，Phe，Tyr，Glu，Ser，Asp或Asn。

    Insulin analogs with enhanced zinc binding
    14.
    发明授权
    Insulin analogs with enhanced zinc binding 有权
    胰岛素类似物具有增强的锌结合

    公开(公告)号：US06686177B1

    公开(公告)日：2004-02-03

    申请号：US09701968

    申请日：2001-05-14

    申请人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke ,  Axel Wollmer

    发明人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke ,  Axel Wollmer

    IPC分类号： A61K3828

    CPC分类号： C07K14/62 ,  A61K38/00 ,  Y10S514/866

    摘要： The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.

    摘要翻译： 本发明涉及具有增强的锌结合能力的胰岛素类似物和与人胰岛素相比具有延迟活性的稳定的锌络合物。 本发明还涉及生产所述胰岛素类似物的方法及其用途，特别是用于治疗I型和II型糖尿病的药物制剂。

    Preparation of pancreatic procarboxypeptidase B, isoforms and muteins thereof and their use
    17.
    发明授权
    Preparation of pancreatic procarboxypeptidase B, isoforms and muteins thereof and their use 有权
    胰腺前羧肽酶B，其同种型和突变蛋白的制备及其用途

    公开(公告)号：US06531294B1

    公开(公告)日：2003-03-11

    申请号：US09532730

    申请日：2000-03-22

    申请人： Paul Habermann

    发明人： Paul Habermann

    IPC分类号： C12P2106

    CPC分类号： C12N9/48

    摘要： Pancreatic carboxypeptidase B or an isoform or a mutein of carboxypeptidase B may be prepared by (a) expressing a natural or unnatural enzymatically inactive precursor form of carboxypeptidase B in a microorganism by secretion, (b) purifying the precursor form expressed by secretion, and (c) converting the purified precursor form into the active form by an enzymatic treatment. A nucleic acid construct and a host cell containing the construct are useful for preparing pancreatic carboxypeptidase B or an isoform or a mutein thereof by this method.

    摘要翻译： 胰腺羧肽酶B或羧肽酶B的同种型或突变蛋白可以通过以下方法制备：（a）通过分泌在微生物中表达天然或非天然的酶促无活性的羧肽酶B的前体形式，（b）纯化由分泌表达的前体形式，和 c）通过酶处理将纯化的前体形式转化成活性形式。 含有该构建体的核酸构建体和宿主细胞可用于通过该方法制备胰腺羧肽酶B或其同种型或突变蛋白。

    Pharmaceutical Composition for Treating A Metabolic Syndrome
    18.
    发明申请
    Pharmaceutical Composition for Treating A Metabolic Syndrome 审中-公开
    用于治疗代谢综合征的药物组合物

    公开(公告)号：US20140142023A1

    公开(公告)日：2014-05-22

    申请号：US14232849

    申请日：2012-06-29

    申请人： Mark Sommerfeld ,  Hans-Ludwig Schaefer ,  Oliver Boscheinen ,  Paul Habermann ,  Ercole Rao ,  Matthias Dreyer

    发明人： Mark Sommerfeld ,  Hans-Ludwig Schaefer ,  Oliver Boscheinen ,  Paul Habermann ,  Ercole Rao ,  Matthias Dreyer

    IPC分类号： A61K38/18 ,  A61K38/26 ,  A61K45/06 ,  A61K38/28

    CPC分类号： A61K38/1825 ,  A61K31/155 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.

    摘要翻译： 本发明涉及包含至少一种FGF-21（成纤维细胞生长因子21）化合物，至少一种GLP-1R（胰高血糖素样肽-1受体）激动剂和任选的至少一种抗糖尿病药物和/ 或至少一种DPP-4（二肽基肽酶-4）抑制剂，用于治疗至少一种代谢综合征和/或动脉粥样硬化，特别是糖尿病，血脂异常，肥胖症和/或脂肪酸。 本发明还涉及包含至少一种FGF-21（成纤维细胞生长因子21）化合物，至少一种DPP-4（二肽基肽酶-4）抑制剂和任选的GLP-1R（胰高血糖素样肽-1受体 ）激动剂和/或至少一种至少一种抗糖尿病药物用于治疗至少一种代谢综合征和/或动脉粥样硬化，特别是糖尿病，血脂异常，肥胖和/或脂肪酸。

    Method for producing insulin analogs having a dibasic B chain terminus
    20.
    发明授权
    Method for producing insulin analogs having a dibasic B chain terminus 有权
    用于生产具有二元B链末端的胰岛素类似物的方法

    公开(公告)号：US08410048B2

    公开(公告)日：2013-04-02

    申请号：US12349854

    申请日：2009-01-07

    申请人： Paul Habermann ,  Frank Zocher

    发明人： Paul Habermann ,  Frank Zocher

    IPC分类号： A61K38/28 ,  A61K38/48 ,  C07K14/62 ,  C12N9/76

    CPC分类号： C07K14/62 ,  C07K2319/035 ,  C07K2319/75 ,  Y02P20/55

    摘要： The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed ligation reaction with lysine amide or arginine amide, or by lysine or arginine which is modified by protective groups, and optionally subsequent hydrolysis.

    摘要翻译： 本发明涉及一种用于通过遗传工程化其前体并在与赖氨酰胺或精氨酸酰胺的酶催化的连接反应中将所述前体转化为相应的胰岛素，或通过被保护性修饰的赖氨酸或精氨酸来生产一种胰岛素的方法 基团和任选的随后的水解。